Login to Your Account



Pharma: Other News To Note


Monday, July 29, 2013
• Astrazeneca plc, of London, and Bristol-Myers Squibb Co., of New York, said the FDA acknowledged receipt of the new drug application resubmission for investigational drug dapagliflozin for the treatment of adults with Type II diabetes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription